6/26/2008 | SS | Bristol-Myers Squibb accepts 97.1% of Kosan Biosciences' shares to complete acquisition
|
6/18/2008 | SS | Bristol-Myers Squibb, Kosan merger clears HSR waiting period; tender offer set to end June 25
|
5/29/2008 | SS | Bristol-Myers Squibb, Kosan Biosciences to combine in $190 million deal
|
5/29/2008 | SS | Market Commentary: Kosan Biosciences shares soar 230% as Bristol-Myers Squibb tenders at $5.50 per share
|
2/9/2007 | PP | Market Commentary: Kosan secures $45.5 million from stock sale; DOR raises $5.49 million
|
2/9/2007 | PP | New Issue: Kosan Biosciences prices $45.5 million direct placement of stock
|
10/26/2006 | BT | Kosan reports cash of $54.3 million, net loss of $7.5 million for third-quarter 2006
|
9/18/2006 | BT | Kosan says KOS-953 could be first in class to reach market
|
8/22/2006 | BT | Kosan names lead Hsp90 inhibitor compounds
|
7/27/2006 | BT | Kosan second-quarter revenues down at $2.7 million
|
7/19/2006 | BTPP | New Issue: Kosan Biosciences receives $50 million equity line
|
7/19/2006 | PP | Market Commentary: Kosan Biosciences gets $50 million equity line; GTC Biotherapeutics plans $17.53 million stock sale
|
6/7/2006 | BT | Kosan presents clinical results showing antitumor activity of Hsp90
|
6/5/2006 | BT | Kosan's KOS-862, KOS-1584 data show some antitumor activity
|
4/4/2006 | BT | Kosan greenshoe exercised, raising size of deal to $27.5 million
|
4/3/2006 | BT | Kosan presents data on its Hsp90 inhibitors program at cancer research meeting
|
3/30/2006 | BT | New Issue: Kosan raises $25 million in spot follow-on of 5 million shares at $5 each vs. $5.88 close
|
3/30/2006 | BT | Market Commentary: Amylin zooms to new high after follow-on; Seattle Genetics dips; Kosan declines 9% on spot sale
|
3/2/2006 | BT | Kosan says 2005 revenue down $9.5 million to $13.4 million, cuts workforce
|
1/25/2006 | BT | Kosan starts phase 1 trial of oral anticancer agent KOS-1022
|
1/4/2006 | BT | Market Commentary: Kosan deal revival speculated; SGX range for IPO emerges; Depomed zooms; PDLI up 5%
|
12/12/2005 | BT | Kosan says KOS-953 shows potential in trials for multiple myeloma
|
12/8/2005 | BT | Kosan begins phase 2 trial of KOS-953 in metastatic breast cancer; phase 1b results promising
|
8/16/2005 | BT | Market Commentary: Kosan retreats further after pulling follow-on; Nektar slips; Acambis off, Electro-Optical IPO seen delayed
|
8/15/2005 | BT | Kosan pulls stock deal ahead of closing
|
8/15/2005 | BT | Market Commentary: Cita defers IPO plans for merger talks; Kosan dives on trial delays; Incyte, Abgenix buyers emerge
|
8/11/2005 | BT | New Issue: Kosan raises $39.4 million in follow-on at $8.75, discounted from $9 close
|
8/11/2005 | BT | Market Commentary: Coley, China Medical ease back; Mpex announces venture capital; Kosan slips; Elan issues retreat
|
8/8/2005 | BT | Market Commentary: Isis declines on earnings, Lilly note conversion but 5.5% convert finds bids; Quest, LabOne higher
|
8/4/2005 | BT | Kosan to sell 4.5 million shares in follow-on offering
|
8/3/2005 | BT | Kosan kept by CSFB at outperform
|
7/18/2005 | BT | Kosan Biosciences obtains $35 million credit facility
|
7/18/2005 | BT | Market Commentary: Momenta off on secondary sale; Geron zooms on Merck pact; ViroPharma up; Amgen quiet
|